Nexstim Plc Supports 7th International Symposium on Navigated Brain Stimulation in Neurosurgery
Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces its support for the 6th International Symposium on Navigated Brain Stimulation, Neurosurgery and Neuromodulation to be held in Berlin on 11-12 October 2015.
The publication of data on pre-surgical navigated TMS mapping continues to increase, demonstrating the risk-benefit and improving outcomes, and support the case for motor mapping being a part of standard care for patients with tumours in presumed eloquent location.
Sessions on pre-surgical motor and speech mapping will look at the application of navigated TMS and navigated repetitive TMS techniques and, for the first time at this symposium, NBS reimbursement will also be discussed.
The symposium is run by Charité-Universitätsmedizin Berlin and Technische Universität München and supported by Nexstim PLC.
Nexstim’s CEO, Janne Huhtala, said: “The popularity of this symposium, which showcases the increasing usage of Nexstim’s NBS system, is testament to the growing importance of pre-surgical mapping for optimal patient outcomes. Following the recent positive news from Nexstim’s Phase III study with NBT® in stroke therapy, we continue to develop our exciting technology across a variety of applications.”
Janne Huhtala, CEO
For further information please visit www.nexstim.com or contact:
Nexstim +358 (0)40 8615046 Janne Huhtala, Chief Executive Officer
UB Securities Ltd (Certified Adviser) +358 (0)9 2538 0254
Consilium Strategic Communications +44 (0)20 3709 5700 Mary-Jane Elliott / Ivar Milligan / Laura Thornton email@example.com
About Nexstim Plc
Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US
aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim’s shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. In H2 2015, the Company received a recommendation from the Data Safety Monitoring Board (DSMB) to continue the Phase III stroke therapy NICHE trial without any modifications. The first interim analysis on the NICHE (Navigated Inhibitory rTMS to Contralesional Hemisphere) trial using NBT® was performed after 81 patients reached their primary safety outcome assessment, on track, at six months post-treatment. For more information please visit www.nexstim.com.
About Transcranial Magnetic Stimulation (TMS) and Repetitive Transcranial Magnetic Stimulation (rTMS)
Transcranial Magnetic Stimulation (TMS) is a non-invasive technique that consists of a magnetic field emanating from a wire coil held outside of the head. The rapidly changing magnetic field induces a stimulating electric field in the brain. In repetitive Transcranial Magnetic Stimulation (rTMS) the coil delivers a rapidly pulsed magnetic field in order to modulate cortical function in a region of the brain.
About Navigated Brain Stimulation (NBS)
Navigated Brain Stimulation is a non-invasive technique that allows accurate and detailed mapping of the critical motor and speech functions of the cortex. Through the use of a standard MRI brain scan, transcranial magnetic stimulation, and EMG, the NBS mapping stimulates areas of the cortex and records motor responses.
About NBT® Navigated Brain Therapy (NBT®) is a non-invasive system that uses navigation to accurately target therapy directly to the cortical structures believed to be involved in brain dysfunctions. The device is CE-marked to offer patients a personalised treatment for major depression. In addition, the system is CE-marked for use in patients recovering from stroke as a supplement to conventional rehabilitation.